Testing a new drug for CD38-positive blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug, SCTC21C, for people with certain blood cancers (like myeloma or lymphoma) that have come back or not responded to other treatments. The goal is to see if the drug is safe and can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and weigh between 88 and 198 pounds.
- You have a blood cancer (like multiple myeloma or lymphoma) that tests positive for a protein called CD38.
- Standard treatments have stopped working or are not an option for you.
- You are able to take care of yourself (up and about most of the day) and have a life expectancy of at least 3 months.
- Your liver, kidney, and heart function are basically normal, and your blood counts are stable enough.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SCTB39G, for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it can shrink tumors and improve survival, and to find the best dose. Participation involves regular treatment and check-ups.
This trial tests a new drug called SCTB39-1 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: first finding the right dose, then testing how well it works.
This study tests a new experimental drug called SCTB35 for people with B-cell lymphoma that has come back or stopped responding to treatment. The drug is designed to target a protein on cancer cells (CD20) and may help your immune system fight the lymphoma.
This study tests a new drug called HRS-3005 in patients with B-cell blood cancers that have come back or stopped responding to prior treatment. The trial aims to find the right dose and understand how well the drug works and what side effects it causes.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests two new investigational drugs (SCTB35 and SCTB41) alone or with chemotherapy for people with B-cell lymphoma that hasn't responded to previous treatments. The goal is to see if these drugs can help shrink or control the lymphoma.
Hear when a new Relapsed or Refractory Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.